This inventor holds 1 USPTO granted patent. Top assignee: Peking University. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: Hongyan Cheng: Innovator in Ovarian Cancer Research
Introduction
Hongyan Cheng is a prominent inventor based in Beijing, China. She has made significant contributions to the field of cancer research, particularly in the development of innovative treatments for ovarian cancer. Her work focuses on the use of T-cell epitope peptides to enhance the efficacy of anti-cancer therapies.
Latest Patents
Hongyan Cheng holds a patent for "T cell epitope peptides of ovarian cancer anti-idiotypic antibody 6B11 and use thereof." This invention provides two T-cell epitope peptides derived from the anti-idiotype antibody 6B11, specifically designed to target ovarian cancer cells. The sequences of these peptides are detailed in SEQ ID NO:3 or 6. The patent outlines the potential use of these peptides in the manufacture of vaccines aimed at treating and preventing ovarian cancer. The T-cell epitope peptides have shown the ability to specifically kill OC166-9 positive ovarian cancer cells, indicating their promising application in cancer therapy.
Career Highlights
Hongyan Cheng is affiliated with Peking University, where she conducts her research and development activities. Her work has garnered attention for its innovative approach to tackling ovarian cancer, a disease that affects many women worldwide. Cheng's dedication to advancing cancer treatment options is evident in her research endeavors.
Collaborations
Hongyan Cheng collaborates with esteemed colleagues, including Heng Cui and Wei Li. These partnerships enhance her research capabilities and contribute to the advancement of cancer therapies.
Conclusion
Hongyan Cheng is a trailblazer in the field of ovarian cancer research, with her patented innovations paving the way for new treatment options. Her contributions are vital in the ongoing fight against cancer, and her work continues to inspire future research in this critical area.